Barclays sets USD 20.00 target for Baxter International stock

Published on 10/17/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 29, 2026. Baxter International stock was last at USD 25.28 on October 16, 2026, down 1.86 percent versus NYSE prior close.

Analyst view and reporting date

Barclays set a USD 20.00 target and Underweight rating on October 7, 2026.
Baxter will discuss third-quarter 2026 results on October 29, 2026.
Baxter International stock was last at USD 25.28 on October 16, 2026 at 4:00 p.m. ET, down 1.86 percent versus the NYSE prior close.
The stock had a USD 13.1 billion market capitalization and a negative 12.40 P/E ratio on October 16, 2026.

Isometrische 3D-Illustration der Medizintechnik-Lieferkette von Rohstoff bis Krankenhaus — Becton Dickinson globale Lieferkette isometrisch als 3D Diagramm visualisiert, Wertpapier US0718131099 NYSE, Illustration mit AI erstellt.

Baxter International stock (ISIN US0718131099) faced a USD 20.00 price target from Barclays, which began coverage with an Underweight rating on October 7, 2026. That target lies 20.89 percent below the latest NYSE price of USD 25.28. According to MarketBeat, Barclays set the target and rating in a research note dated October 7, 2026. Baxter International stock was last at USD 25.28 on October 16, 2026 at 4:00 p.m. ET, down 1.86 percent versus the NYSE prior close.

Results arrive October 29

The next scheduled company event is Baxter's discussion of its third-quarter 2026 financial results on October 29, 2026. Baxter said on October 7, 2026 that the conference call would begin at 7:30 a.m. Central Time. The date gives investors the next scheduled checkpoint for the company's 2026 performance.

Stock remains below yearly high

Baxter International stock had a 52-week range of USD 15.73 to USD 30.00 on October 16, 2026. The latest price stood 15.73 percent below the upper end of that range, while the market capitalization was USD 13.1 billion. Trading volume reached 4,406,363 shares, compared with an average volume of 6,507,742 shares, on the same date.

Valuation and peer comparison

The stock carried a negative 12.40 P/E ratio and a USD 13.1 billion market capitalization on October 16, 2026. These figures frame the Barclays target ahead of the October 29 results discussion. Baxter's healthcare portfolio includes infusion, injectable medicines, surgical and connected-care products, according to the company's business description on its website.

Comparison with peers

Baxter International (NYSE, USD): minus 1.86 percent, P/E minus 12.40, market capitalization USD 13.1 billion
Medtronic (NYSE, USD): minus 0.73 percent, P/E 23.34, market capitalization USD 121.2 billion
Becton, Dickinson and Company (NYSE, USD): minus 1.04 percent, P/E 57.76, market capitalization USD 52.2 billion

Price and market position

The USD 25.28 last price on October 16, 2026 placed Baxter below its 52-week high of USD 30.00, with the stock's negative P/E ratio and the October 29 reporting date providing the main reference points for the next session.

Market context: Market report S&P 500.

More news and analyses on Baxter International stock